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Abstract
Background: HPV vaccines have demonstrated high efficacy in clinical trials against
cervical lesions and infections by HPV vaccine types 16 and 18. Together these two
types are responsible for approximately 70% of cervical cancer. Data on HPV vaccine
effectiveness in general populations is limited.
Methods: Surveillance data monitoring high-grade cervical lesions in Connecticut was
used. Medical records were reviewed and patients were interviewed to ascertain HPV
vaccine history. Patients’ biopsy specimens were typed to determine the presence of
vaccine or non-vaccine type HPV. Odds ratios were determined using logistic
regression, adjusting for age at diagnosis, grade of cervical lesion, race/ethnicity, and
insurance type.
Results: From 2008-2012, 788 women with known vaccine status and typed biopsy
specimens were analyzed. 8.9% of women received at least one vaccine dose.
Adjusted vaccine effectiveness for at least one dose was estimated to be 53%. Vaccine
type HPV was strongly associated with higher grade cervical lesions, but other
statistically significant associations were not found.
Conclusions: The data suggests that HPV vaccination provides protection against
vaccine type high-grade cervical lesions in women. Although these results are
promising, more long term data and greater sample sizes are required to better estimate
vaccine effectiveness.
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Introduction

Human papillomavirus (HPV) is the most common sexually transmitted infection
in the United States [1]. The overall prevalence for genital HPV infection is 26.8% for
American women between 14 and 59 years old, with the highest prevalence in women
20-24 years old (44.8%) [2]. There are over 100 human papillomavirus types that infect
humans [3]. Of these, more than 40 types of HPV that infect the anogenital tract have
been identified [4]. Most HPV infections are cleared without treatment in about 12
months, nononcogenic strains clearing faster than oncogenic strains [5]. Persistent
infections that do not clear can progress to precancerous cervical lesions and cervical
cancer. HPV is detected in over 99% of cervical carcinomas and is a necessary cause
of cervical cancer [6]. HPV is also associated with a high number of vaginal, anal,
vulvar, and penile cancers, as well as various head and neck cancers and genital warts
[7].
HPV types can be categorized as high risk, probable high risk, and low risk [4].
Low risk types are generally associated with genital warts and high risk with cervical
lesions and cancer. Worldwide, approximately 70% of invasive cervical cancer is
caused by HPV types 16 and 18 [8]. Gardasil, a quadrivalent vaccine that protects
against high risk types 16 and 18 and low risk types 6 and 11 was approved by the
Food and Drug Administration (FDA) for use in females age 9-26 in 2006 [9]. In 2009, a
bivalent vaccine that protects against types 16 and 18, Cervarix, was approved for
females age 10-25 [10]. The current Advisory Committee for Immunization Practices
(ACIP) recommendations are routine vaccination for females age 11-12 with either the
quadrivalent or bivalent vaccine and for males age 11-12 with the quadrivalent vaccine
6

only [9, 11, 12]. Permissive or catch-up vaccination is recommended up to age 26.
Both the quadrivalent and bivalent vaccines have shown over 95% efficacy in clinical
trials for prevention of cervical infections in HPV-naïve women [13-16]. The bivalent
vaccine has also shown cross-protective efficacy against four oncogenic non-vaccine
types and three low risk types [17, 18].
In 2012, 34.5% of women age 19-26 in the United States were estimated to have
received at least one dose of HPV vaccine [19]. This was a slight increase from 29.5%
coverage in 2011 and 20.7% coverage in 2010 [20, 21]. Among girls age 13-17, the
estimated coverage for one dose or more has increased from 25.1% in 2007 to 53.8%
in 2012 [22]. The 2012 coverage for the state of Connecticut of 57.6% was slightly
higher than the national average, however there was no increase from 60.5% estimated
coverage in 2011 [23, 24].
Cervical intraepithelial neoplasia (CIN) and adenocarcinoma in situ (AIS) are
precancerous cervical lesions caused by HPV. These lesions do not necessarily
progress into cancer and some may regress [25, 26]. The high risk strains are usually
associated with these lesions, but low risk strains can also cause CIN 1 and CIN 2 [27].
CIN is 1 referred to as a low-grade lesion, while CIN 2, CIN 3, and AIS are considered
high-grade. CIN 2 is the current recommended treatment threshold, but observation is
the preferred course of action for younger women who are more likely to have natural
regression [28]. In 2010, screening guidelines changed to no longer screen women
under the age of 21 because of the rarity of cervical cancer in women that age and high
probability of regression [29]. Cervical cancer incidence and mortality has overall
declined greatly in developed nations since the 1960s and 1970s due to screening
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programs and improved treatment. However, there are recent increases in young
women in some countries, which may be a result of generational differences in sex
habits [30].
Evidence of overall vaccine impact can currently be best detected through
prevalence of vaccine type HPV and diagnoses of genital warts, while vaccine impact
on high-grade cervical lesions and cancer will take longer to fully demonstrate because
these conditions take years to decades to develop [31]. Reports of reduced prevalence
of vaccine type HPV and genital warts in the United States and other countries provides
early evidence of vaccine impact [32]. Previous HPV-IMPACT results also suggest
vaccine impact; a significantly lower proportion of CIN2+ caused by vaccine type HPV
was found in women who were vaccinated greater than 24 months before their trigger
Pap [33].
In Australia, an extensive vaccination program began in 2007 for in school routine
vaccination for girls 12-13 and catch-up vaccination for girls 13-17, along with
community catch-up vaccination for women 18-26. The incidence of high-grade cervical
lesions in females under age 18 was found to be significantly reduced after induction of
this program; however, incidence for females in other age groups did not change
significantly [34]. Evidence for quadrivalent vaccine effectiveness against cervical
abnormalities has begun to emerge from this program in Australia as well. A casecontrol study using anonymous, linked registry data for vaccination status and
development of cervical abnormalities detected upon first Pap screening found
statistically significant protection against these abnormalities in young women [35].
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The Connecticut HPV-IMPACT group has already reported significantly declining
rates of high-grade cervical lesions in the state for women ages 21-24 years [36]. The
same analysis also found significant declines in census tracts with lower proportions of
the population black, Hispanic, or living below the federal poverty level and in nonurban
areas. Another study by the group found black race, Hispanic ethnicity, and higher
area-based poverty to be associated with lower likelihood of vaccine-type HPV [37].
This suggests that the vaccine may have lower impact among these women. The group
has published other findings on racial/ethnic and economic disparities in HPV
vaccination and high-grade cervical lesion diagnoses [38-40].
Pooled analysis of quadrivalent vaccine efficacy from three clinical trials
demonstrates over 95% efficacy against high-grade cervical lesions for per-protocol
treatment [13]. However in these trials participants were excluded if they had prior
abnormal Pap results, over four lifetime sex partners, or prior confirmed HPV disease.
This does not accurately represent actual populations of women at risk for high-grade
cervical lesions. Similarly high efficacy was found for the bivalent vaccine in clinical
trials, and in addition women were included irrespective of their HPV status and
cytology, but were excluded if they had more than six lifetime sex partners or previous
colposcopy [14]. This is more inclusive, but still not fully representative and may not be
as applicable, as almost all HPV vaccines administered in the United States from 20062010 were the quadrivalent vaccine [41].
In 2010, over 11,800 women were diagnosed with cervical cancer in the United
States and over 3,900 women died from the disease [42]. Over one million women are
diagnosed with low-grade cervical lesions each year and approximately 500,000 are
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diagnosed with high-grade lesions [28, 43]. The cost for one instance of these
diagnoses can range from approximately $1,000 for CIN1 to over $3,000 for CIN3, and
overall cost of management of precancerous cervical lesions was approximately 17% of
total cervical HPV related costs for one health plan [44]. The estimated annual baseline
cost per case for cervical cancer was $38,800 in 2010 US dollars [45]. Diagnoses with
these conditions can also have negative psychological impact such as fear of cancer,
infertility, or loss of sexual function; depression; sleep disturbance; anxiety; and
embarrassment [46, 47].
Given the physical, financial, and psychological burden of HPV related cervical
lesions, there is a definite need for preventative action. HPV vaccines have shown very
high efficacy in clinical trials, but at this time there is limited data on the effectiveness of
these vaccines at preventing vaccine type lesions in real world populations. This
analysis attempts to estimate vaccine effectiveness in the entire population of young
women in New Haven County, Connecticut using surveillance data. This study aims to
fill the knowledge gap on HPV vaccine effectiveness against high-grade cervical lesions
using individual vaccination status and typed HPV specimens.

Methods
Surveillance System
In 2008, the Centers for Disease Control and Prevention (CDC) began monitoring
HPV vaccine impact through the Emerging Infections Program (EIP) network using
population-based surveillance of high-grade cervical lesions [48]. On January 1st, 2008,
the Connecticut Department of Public Health designated CIN 2 and higher and AIS as
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mandatory reportable diseases in the state [49]. All pathology labs in the state are
required to report these diagnoses. The reports contain the diagnostic information and
patient demographics. Reports were reviewed by EIP staff for eligibility and accuracy
and then entered into a database.

Medical Record Review and Patient Interviews
Enhanced surveillance was conducted for New Haven County residents between 18
and 39 years old at the time of diagnosis. EIP staff reviewed available medical records
of these patients from the provider who performed the biopsy that produced the
diagnosis. Medical records were reviewed for HPV vaccination status, cervical cancer
screening history (including the date and results of the abnormal “trigger” Pap that lead
to the biopsy and diagnosis), as well as demographic and contact information that may
have been missing from the initial report. EIP staff then conducted telephone interviews
with these patients which touched on similar information to the medical record review.
Patients were asked if they received the vaccine. Patients who reported receiving the
vaccine were then asked if it was the quadrivalent or bivalent vaccine and when and
from which provider they received each dose. All patients were then asked
demographic questions concerning race, ethnicity, and type of insurance at the time of
diagnosis.
Vaccination history was verified with providers for patients who reported being
vaccinated. The Connecticut HPV-IMPACT group has previously analyzed the
concordance of vaccination history from patient interviews and medical records [50].
Concordance of vaccination history was found to be relatively high at 83%, with 96%
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sensitivity (percentage of women who had a history of vaccination from medical record
and reported vaccination from patient interview) and 97% specificity (percentage of
women who had did not have a history of vaccination from medical record and reported
not being vaccinated during patient interview). Although concordance was good, there
was a high frequency of missing data. Vaccination history was missing from 34% of
medical records and 43% of patients could not be reached for interview.

HPV Typing
Biopsy specimens from New Haven County women age 18-39 were requested from
pathology laboratories. For patients with more than one available tissue block, the
block representative of the highest grade lesion was selected by a pathologist.
Available samples were shipped to the CDC for DNA extraction and HPV typing. HPV
typing was performed using polymerase chain reaction (PCR); more detailed methods
have been described elsewhere [33, 51].

Covariates
For this analysis, age at diagnosis was collapsed into five categories, 18-20, 21-24,
25-29, 30-34, and 35-39. These categories were chosen to remain consistent with
other HPV-IMPACT analyses [51]. Race categories for patient interviews were white,
African American, Asian, American Indian/Alaskan American, other, unknown, and
multi-race. Ethnicity was recorded as Hispanic, not Hispanic, or unknown. Race and
ethnicity were combined for this analysis as Hispanic, White (not Hispanic), African
American (not Hispanic), other (not Hispanic), and unknown. Asian, American
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Indian/Alaskan American, other, and multi-race were combined into the other category
because of low frequency. Insurance was categorized as private, public (Medicaid,
state assistance, or Medicare), uninsured (no coverage or self-pay), other, and
unknown. Diagnosis was categorized as CIN 2, CIN 2/3, CIN 3, and AIS (AIS alone or
in conjunction with CIN 2, CIN 2/3, or CIN 3).

Case Definition and Vaccination Status
HPV type was categorized as 16/18 (vaccine type), other high risk types, possible
high risk types, and low risk types. Risk categories were chosen to be consistent with
previous HPV-IMPACT analyses and current HPV epidemiologic classification [4, 51].
Patients who tested positive for two or more different HPV types were categorized using
a hierarchy ranked in the order of 16/18, other high risk, possible high risk, and low risk.
Samples were categorized into the highest hierarchical group. This was further
collapsed into vaccine type (16/18) and non-vaccine type (other high risk, possible high
risk, and low risk) for analysis.
Vaccine status was defined as having at least one dose of either HPV vaccine.
Vaccine status was categorized using time from the date of the first dose of the vaccine
to the date of the trigger Pap that lead to the high-grade cervical lesion diagnosis.
Vaccination status was classified as not vaccinated, vaccinated at or after trigger Pap,
vaccinated within one year before trigger Pap, vaccinated within two years before
trigger Pap, vaccinated within three years before trigger Pap and vaccinated three or
more years before trigger Pap. Patients with verified vaccination status and unknown
trigger Pap dates were classified as vaccinated at or after trigger Pap. Vaccine status
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was further collapsed for the analysis so that only patients vaccinated two years or more
before trigger Pap were considered vaccinated. Patients vaccinated less than two
years before trigger Pap were considered unvaccinated. The time frame of two years or
more was chosen based on previous HPV-IMPACT results showing significantly lower
proportion of vaccine type HPV in women vaccinated at this time and no significant
effect on women vaccinated less than 24 months before trigger Pap [33].

Statistical Analysis
Analysis was restricted to women with known vaccine status and known HPV type.
If a patient had more than one high-grade cervical lesion event reported, only the first
event was used.

Chi-square tests were used to assess associations between HPV

type and covariates, using P<0.05 level of significance. Unadjusted and adjusted odds
ratios and 95% confidence intervals were estimated using logistic regression. The
model was reduced to adjust for covariates using backwards elimination. Vaccine
effectiveness was estimated using the formula (1 – adjusted odds ratio) x 100%. All
analyses were done using SAS statistical software (version 9.3, SAS Institute, Cary,
NC). Flowchart was constructed using Lucidchart (https://www.lucidchart.com/).

Results
In total, 4,327 individual women were diagnosed with high-grade cervical lesions
in New Haven County from 2008-2014 (from the inception of surveillance to the
beginning of data analysis). Of these women, 2,129 had known vaccine status (1,890
not vaccinated, 239 vaccinated) and 2,198 had unknown vaccine status. The total
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number of typed specimens was 1,308 (740 non-vaccine type, 568 vaccine type) for all
women. HPV type was not available for the remaining 3,019 women for various
reasons, including pending specimen requests from pathology labs, samples that were
insufficient for typing, or specimens that tested negative for all HPV types; this has been
discussed in a previous HPV-IMPACT study [37]. Overall 520 typed specimens were
excluded because of missing vaccine history and 169 vaccine status known women
were excluded because of unknown HPV type. See figure 1 for further detail on
inclusion and exclusion frequency.
When unknown strata were excluded, the included and excluded groups had
similar distribution by percentage for HPV type, vaccination status, and age at first
vaccine dose. Age at diagnosis distribution was skewed slightly towards older age
groups in the excluded women, with mean and median age for the included women
(27.4±5.25, 26.6) slightly lower than the excluded women (28.3±5.16, 27.8). There was
a small difference between the two groups for diagnosis distribution, with higher grade
outcomes in the excluded group. For known race/ethnicity in the two groups, the
percentage black and other were similar, but the included groups had a higher
percentage white (63.38% to 50.35%) and lower percentage Hispanic (20.07% to
33.82%). There were also differences between the two groups for insurance type. The
included women had a higher percentage private insurance (73.10% to 56.95% and
lower percentage public insurance (24.80% to 38.04%).
A total of 788 women with known vaccine status and HPV type were used in the
final analysis. Typed specimens were only available for 2008-2012. Tables 1 and 2
present the basic demographics for the sample analyzed. There were no statistically
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significant differences between the vaccine type and non-vaccine type groups for
vaccine history, age at vaccination, age at diagnosis, race/ethnicity, type of insurance,
and year of diagnosis. There was a significant difference between the two groups for
cervical lesion diagnosis. The vaccine type group had more higher grade outcomes
than the non-vaccine type group.
Odds ratios are presented in table 3. Odds ratios for AIS were not calculated
due to small sample size. Differences in odds ratios between the unadjusted, full, and
reduced models were small. The most statistically significant covariate was cervical
lesion grade in all models. Although race/ethnicity and insurance were not found to be
statistically significant in any model, they were kept in the final model because they
have been found to be significantly associated with vaccine type HPV in previous HPVIMPACT studies [37]. The final adjusted odds ratio for vaccinated status compared to
unvaccinated was 0.47 (95% confidence interval 0.27-0.82) for vaccine type HPV. This
equates to a vaccine effectiveness of 53%.
Figure 2 displays vaccine type trends through total typed cases per year,
regardless of vaccination history of patients, to demonstrate crude potential vaccine
impact on type distribution over time. Non-vaccine and vaccine types were charted as a
percentage of total specimens with known type per year, with frequencies for each year
tabled under the figure. There was a large difference in number of cases for both types
between the different years, but this is attributable to more complete data from earlier
years, with more pending data on HPV type for later years.
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Discussion
A significant association was found between vaccine status and HPV type.
Estimated vaccine effectiveness of 53% is consistent with other HPV vaccine
effectiveness analyses, although an analysis using outcome measures of high-grade
cervical lesion diagnoses and HPV type is not currently available to the best of our
knowledge. The 2013 analysis by Markowitz et al using nationally representative US
data from the National Health and Nutrition Examination Surveys (NHANES) reported
82% effectiveness for at least one dose of the quadrivalent vaccine against types 6, 11,
16, and 18 infection in females 14-19 years old [41]. This study also found no
difference in pre and post vaccine period HPV prevalence in other age groups. The
2014 study by Crowe et al reported 46% effectiveness against high-grade lesions and
34% effectiveness against other abnormalities for the complete three dose series of the
quadrivalent vaccine in females 11-27 years old in Queensland, Australia [35]. This
study used cervical abnormalities caused by any HPV type as an outcome measure and
specimens were not typed.
Of women who were ever vaccinated, 38% received the first dose at or after the
date of their trigger Pap. This is consistent with previous analysis of this study
population. It was suggested that abnormal cytology prompted vaccination and racial
disparities in vaccination before and after this time were noted [38]. Significant
differences in age, race, and insurance status have also been reported for patients with
vaccine initiation at or after trigger pap [33].
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Our study has several strengths, the first being use of individual HPV type, highgrade cervical lesion diagnosis, and vaccination history together in one analysis.
Second, vaccination history was verified and not based solely on self-report. Third,
medical records were reviewed for almost every case (approximately 1% of medical
records are unavailable for review) [50]. Fourth, because high-grade cervical lesions
are a mandatory reportable condition in the state of Connecticut, our raw data
represents outcomes in our entire population at risk. In addition, these conditions are
reported using a common grading system, helping to ensure accurate disease
classification.
There are some limitations to our study. First, we had a large amount of missing
data. HPV type was not available for 70% of patients and vaccine status was unknown
for 51% of women. Race and ethnicity data was also not available for 28% of women
analyzed. Missing data resulted in a smaller sample size and more limited time frame
for analysis. This also limited ability to analyze trends in HPV type over time to monitor
vaccine impact. Second, there is a possibility of selection bias in patient interviews with
respect to women who were able to be contacted and agreed to the interview and those
who were not interviewed. Third, sample size for vaccinated women was very small
compared to unvaccinated women; however, this may be accurately representative of
the population and not due to selection bias.
Lastly, cervical cancer screening guidelines changed in 2010 to discontinue
screening women under the age of 21 [29]. Data from before and after the change in
recommendations might no longer be as comparable, as fewer cases may be captured
now. However, it is unknown at this time how many providers are following these new
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guidelines and what the magnitude of difference in screening for women age 18-20 is
before and after the change in guidelines. In addition, new 2012 guidelines for
screening once every three years for women age 21-29, and once every five years for
women 30 and over may have similar effects [52]. This likely had little impact on the
current study, but will be something to consider in the future. It is possible that high
grade cervical lesion rates will decline in our population in the upcoming years, but
whether the declines are the result of vaccine impact or changes in screening guidelines
will need to be examined more closely.
Our analysis adds to the limited evidence for HPV vaccine effectiveness against
vaccine type high-grade cervical lesions. Over time, larger sample size and increased
vaccine impact should strengthen data for this project. Vaccine effectiveness estimates
should become clearer as more vaccinated women reach an age of greater risk for
these high-grade lesions. These preliminary results on vaccine effectiveness in our
population are encouraging and provide support to current recommendations of routine
HPV vaccination for girls.
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Table 1. Sample description for women with known vaccination status and typed
specimens, 2008-2012
HPV type
16/18 Vaccine Type
Other High Risk
Possible High Risk
Low Risk
Vaccination status
Not vaccinated
At or after trigger Pap
1 year or less before trigger Pap
1-2 years before trigger Pap
2-3 years before trigger Pap
3+ years before trigger Pap
Age at first vaccine dose
Not Vaccinated
15-16
17-18
19-20
21-22
23-24
25-26
27 or older
Age at diagnosis
18-20
21-24
25-29
30-34
35-39
Diagnosis
CIN2
CIN2/3
CIN3
AIS/AIS+CIN
Race and ethnicity
Hispanic
White, not Hispanic
Black, not Hispanic
Other, not Hispanic
Race and ethnicity NA

Frequency

Percent

340
392
44
12

43.15
49.75
5.58
1.52

541
99
28
50
35
35

68.65
12.56
3.55
6.35
4.44
4.44

541
5
20
48
75
60
34
5

68.65
0.63
2.54
6.09
9.52
7.61
4.31
0.63

58
247
253
144
86

7.36
31.35
32.11
18.27
10.91

523
94
167
4

66.37
11.93
21.19
0.51

114
360
74
20
220

14.47
45.69
9.39
2.54
27.92
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Table 1. Continued
Insurance
Private
Public
Uninsured
Other Insurance
Insurance NA
Year of diagnosis
2008
2009
2010
2011
2012
Column percentages
NA = not available

Frequency

Percent

557
189
14
2
26

70.69
23.98
1.78
0.25
3.3

295
187
171
122
13

37.44
23.73
21.7
15.48
1.65
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Table 2. Sample description for women with known vaccine status stratified by HPV
type

Vaccine status
Not vaccinated
Vaccinated
Total
Age at vaccination
Not Vaccinated
15-20
21+
Diagnosis
CIN2
CIN2/3
CIN3
AIS/AIS+CIN
Age at diagnosis
18-20
21-24
25-29
30-34
35-39
Race and ethnicity
Hispanic
White, not Hispanic
Black, not Hispanic
Other, not Hispanic
Race and ethnicity NA
Insurance type
Private
Public
Uninsured
Other Insurance
Insurance NA
Year of diagnosis
2008
2009
2010
2011
2012
Column percentages

Non-vaccine
Type n (%)

Vaccine Type
n (%)

Total

399 (89.06)
49 (10.94)
448

319 (93.82)
21 (6.18)
340

718
70
788

Χ2
probability
0.0200

0.0855
294 (65.63)
48 (10.71)
106 (23.66)

247 (72.65)
25 (7.35)
68 (20.00)

541
73
174
<.0001

336 (75.00)
43 (9.60)
69 (15.40)
0
(0)

187 (55.00)
51 (15.00)
98 (28.82)
4
(1.18)

523
94
167
4

34 (7.59)
144 (32.14)
127 (28.35)
87 (19.42)
56 (12.50)

24 (7.06)
103 (30.29)
126 (37.06)
57 (16.76)
30 (8.82)

58
247
253
144
86

0.0919

66 (14.73)
186 (41.52)
48 (10.71)
13 (2.90)
135 (30.13)

48 (14.12)
174 (51.18)
26 (7.65)
7
(2.06)
85 (25.00)

114
360
74
20
220

0.0812

309 (68.97)
113 (25.22)
7
(1.56)
1
(0.22)
18 (4.02)

248 (72.94)
76 (22.35)
7
(2.06)
1
(0.29)
8
(2.35)

557
189
14
2
26

0.5537

167 (37.28)
115 (25.67)
89 (19.87)
68 (15.18)
9
(2.01)

128 (37.65)
72 (21.18)
82 (24.12)
54 (15.88)
4
(1.18)

295
187
171
122
13

0.3880
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Figure 1. Flow chart of New Haven County women diagnosed with CIN2+, 2008-2014
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Figure 2. Bar graph of changes in non-vaccine type and vaccine type distribution over
time as a percentage of total specimens, with table of all typed specimens per year
below
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Table 3. Unadjusted and adjusted odds ratios for vaccine type
Unadjusted
Full model
OR (95% CI)
OR (95% CI)
Vaccination status
Not Vaccinated
1.00 (Reference)
1.00 (Reference)
Vaccinated
0.54 (0.32-0.91)** 0.57 (0.30-1.08)*
Age at first vaccine dose
Not Vaccinated
1.00 (Reference)
1.00 (Reference)
15-20
0.62 (0.37-1.04)*
0.74 (0.37-1.49)
21+
0.76 (0.54-1.08)
0.74 (0.48-1.12)
Age at diagnosis
18-20
1.00 (Reference)
1.00 (Reference)
21-24
1.01 (0.57-1.81)
0.97 (0.50-1.87)
25-29
1.41 (0.79-2.51)
1.11 (0.55-2.23)
30-34
0.93 (0.50-1.73)
0.68 (0.32-1.42)
35-39
0.76 (0.38-1.51)
0.48 (0.21-1.07)*
Diagnosis
CIN 2
1.00 (Reference)
1.00 (Reference)
CIN 2/3
2.13 (1.37-3.32)*** 2.13 (1.35-3.35)***
CIN 3
2.55 (1.79-3.64)*** 2.61 (1.81-3.77)***
AIS
Sample size too small
Race/ethnicity
White, not Hispanic
1.00 (Reference)
1.00 (Reference)
Hispanic
0.90 (0.60-1.35)
0.91 (0.59-1.40)
Black, not Hispanic
0.67 (0.41-1.11)
0.74 (0.43-1.25)
Other
0.67 (0.26-1.70)
0.68 (0.26-1.80)
Insurance type
Private
1.00 (Reference)
1.00 (Reference)
Public
0.86 (0.62-1.20)
0.78 (0.54-1.12)
Uninsured
1.28 (0.44-3.69)
0.95 (0.32-2.86)
Other
1.28 (0.08-20.52)
1.41 (0.08-23.62)
OR= odds ratio; CI = confidence interval
*P<0.10; **P<0.05; ***P<0.01

Reduced model
OR (95% CI)
1.00 (Reference)
0.47 (0.27-0.82)***

1.00 (Reference)
0.99 (0.54-1.80)
1.23 (0.68-2.24)
0.80 (0.42-1.52)
0.56 (0.27-1.16)
1.00 (Reference)
2.14 (1.36-3.37)***
2.65 (1.83-3.82)***

1.00 (Reference)
0.93 (0.60-1.43)
0.76 (0.45-1.29)
0.69 (0.26-1.83)
1.00 (Reference)
0.78 (0.55-1.13)
1.00 (0.33-2.97)
1.41 (0.08-23.68)
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